Metastatic colorectal cancer – Tumor location, left or right, impacts efficacy in KRAS/RAS wild-type patients
Background Metastatic colorectal cancer, mCRC, is a group of distinct diseases, with clinical and molecular differences between right-sided and left-sided tumors driving varying prognosis. Patients
HER2 breast cancer patients! 6% complete remission 54.9% shrinkage with Trastuzumab Deruxtecan, DS-8201
When was it reported? The outcome of the phase II, multicenter, open-label, single-arm DESTINY-Breast trial was reported at the 2019 San Antonio Breast Cancer Symposium,
Combination of Two FDA Approved Drugs Shows Promise in BRAF V600E‒Mutated Glioma
In short The results of a phase II trial in patients with BRAF V600E mutations in high- and low-grade glioma, were reported at the 24th
Potential Cure of recurrent GBM with the Oncolytic Herpes Virus G47∆
Interim results The virus has been designated a breakthrough therapy in Japan. An interim analysis of a trial of the oncolytic herpes virus G47∆ has
Glioblastoma Moltiforme, GBM – NEW immunotherapies stop from growing in newly diagnosed patients
Background According to interim findings of a phase II trial, the combination of INO-5401, a T-cell–activating immunotherapy and INO-9012, an immune activator of a different
New anti-cancer drug, Tucatinib, reduces risk of death in metastatic HER2+ breast cancer
Background There is significant unmet medical need following treatment with Herceptin, Perjeta and Kadcyla in patients with metastatic HER2-positive breast cancer. In the HER2CLIMB trial,
Approved immunotherapy has shown a positive survival benefit in HER2+ breast cancer
This time, we’ll start from the end… Results of the study First of all, it is important to note that the research goals were not
Small Cell Lung Cancer, SCLC – Treatment with an approved drug, Onivyde, shows efficacy
Many small cell lung cancer patients rapidly relapse due to the aggressive nature of the disease. While the current standard of care in the second-line
Lung cancer patients, heard already about Capmatinib?
The Food and Drug Administration, the FDA, has granted capmatinib a “breakthrough therapy” designation as a first-line treatment for Non-Small Cell Lung Cancer (NSCLC) patients
This Trial Achieved Complete Disappearance of Disease in Metastatic Kidney Cancer
The main therapeutic objectives in treating metastatic disease are prolonging life (also called “Survival”) and Quality of Life (QoL), knowing the disease will stay in
Pancreatic Cancer – between 2 to 3 times survival with SM-88
Background The National Comprehensive Cancer Network, NCCN, is the health body which sets the world guidelines in treating cancer. The NCCN recommends clinical trials as
New drug may become the new standard of care for patients with small cell lung cancer, SCLC
Don’t miss opportunities to get drugs like this in a clinical trial setting! Why? Lurbinectedin monotherapy as a second-line therapy in patients with small cell
